Sorbonne University, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Department of Virology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
HIV Med. 2017 Oct;18(9):696-700. doi: 10.1111/hiv.12508. Epub 2017 Apr 26.
Transmitted drug resistance (TDR) can impair the response to first-line antiretroviral therapy. In treatment-naïve patients chronically infected with HIV type 1 (HIV-1), it was previously shown through Sanger sequencing that TDR was more common in men who have sex with men (MSM) than in other transmission risk groups. We aimed to compare two HIV-1 transmission groups in terms of the presence of TDR mutations.
We investigated, through Sanger sequencing and ultradeep sequencing (UDS), the presence of resistance mutations, both in majority (> 20%) and in minority (1-20%) proportions, in 70 treatment-naïve MSM and 70 treatment-naïve heterosexual patients who recently screened positive for HIV-1.
The global prevalence of TDR was not significantly different between the two groups, either by Sanger or by UDS. Nevertheless, a higher frequency of nucleoside reverse transcriptase inhibitor TDR was observed among heterosexual patients (P = 0.04). There was also a trend for a higher frequency of TDR among MSM infected with HIV-1 subtype B compared with MSM infected with HIV-1 non-B subtypes (P = 0.06).
Ultradeep sequencing UDS allowed sensitive monitoring of TDR, and highlighted some disparities between transmission groups.
传播性耐药(TDR)可影响一线抗逆转录病毒治疗的疗效。在初治的慢性 HIV-1 感染者中,通过 Sanger 测序先前已证实,男男性行为者(MSM)比其他传播风险群体更易发生 TDR。本研究旨在比较两种 HIV-1 传播群体中 TDR 突变的存在情况。
通过 Sanger 测序和超高深度测序(UDS),我们调查了 70 名初治 MSM 和 70 名初治异性恋新近 HIV-1 筛查阳性的患者中,耐药突变的存在情况,包括主要(>20%)和次要(1-20%)比例的耐药突变。
两种群体之间,通过 Sanger 或 UDS 检测,TDR 的总体流行率均无显著差异。然而,异性恋患者中核苷逆转录酶抑制剂 TDR 的频率更高(P=0.04)。与感染非 B 亚型 HIV-1 的 MSM 相比,感染 HIV-1 B 亚型的 MSM 中 TDR 的频率也更高,但差异无统计学意义(P=0.06)。
UDS 超高深度测序可灵敏监测 TDR,并突出了不同传播群体之间的一些差异。